RxDoctor Payments Data

Luis Cabrera, MD

Family Medicine · North Miami Beach, FLNPI 1902912454

Payments from drug & device makers

$705,460in general payments, 2019–2025

Across 113 payments — averaging $6243.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Currax Pharmaceuticals LLC$385K
  • Pfizer$306K
  • AstraZeneca$14K
  • Sunovion Pharmaceuticals Inc.$145
  • Otsuka America Pharmaceutical, Inc.$125
  • Novartis$122
  • plus $213 from 5 others

What the payments were for

  • Food & beverage$679100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$705,460 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$18,790
Medicare patients
113
Services billed
391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$134,412
JanuviaSitagliptin Phosphate50$70,395
LinzessLinaclotide66$47,743
JardianceEmpagliflozin39$45,161
XareltoRivaroxaban22$26,996
EntrestoSacubitril/Valsartan28$20,088
TradjentaLinagliptin11$16,623
FarxigaDapagliflozin Propanediol13$13,719
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$12,369
SymbicortBudesonide/Formoterol Fumarate26$11,154
MyrbetriqMirabegron12$10,505
BrilintaTicagrelor21$9,112
LumiganBimatoprost13$7,482
Repatha SyringeEvolocumab11$6,176
Spiriva HandihalerTiotropium Bromide11$5,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$306,363$134,412100 claims
Boehringer IngelheimJardiance, Tradjenta$23$61,78450 claims
AstraZenecaFarxiga, Symbicort, Brilinta$13,500$33,98460 claims
NovartisEntresto$122$20,08828 claims
GSKTrelegy Ellipta$16$12,36914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in North Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →